ERBB2 and neoplasm: Indeed, among 1061 early breast cancer patients of all subtypes, improved survival was previously reported for patients who achieved pCR, especially for HER2 + /HR− tumour subtypes with a 5-year overall survival rate of 83% with pCR versus 50% without pCR49.